Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797089 | 0.93 | BMP1 (0.40) | BMP1MMP3MEN1KMT2AL3MBTL1 | |
| SCHEMBL8159510 | 0.89 | BMP1 (0.40) | BMP1MMP3MEN1KMT2AL3MBTL1 | |
| SCHEMBL6796530 | 0.84 | MMP3 (0.54) | BMP1MMP3MEN1KMT2AL3MBTL1 | |
| SCHEMBL6797426 | 0.83 | MMP2 (0.49) | BMP1MMP3MEN1KMT2AL3MBTL1 | |
| SCHEMBL6797425 | 0.83 | MMP2 (0.49) | BMP1MMP3MEN1KMT2AL3MBTL1 | |
| SCHEMBL6806356 | 0.78 | MMP2 (0.53) | BMP1MMP3MEN1KMT2ACA12 | |
| SCHEMBL6797086 | 0.77 | MMP2 (0.49) | BMP1MMP3MEN1KMT2AL3MBTL1 | |
| SCHEMBL6797087 | 0.77 | MMP2 (0.49) | BMP1MMP3MEN1KMT2AL3MBTL1 | |
| SCHEMBL6797063 | 0.77 | MMP3 (0.50) | BMP1MMP3MEN1KMT2AL3MBTL1 | |
| SCHEMBL6797049 | 0.75 | BMP1 (0.71) | BMP1MMP3MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977745-B1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORP (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040034071-A1 | Thioaryl sulfonamide hydroxamic acid compounds | PHARMACIA CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-6087359-A | A MATRIX METALLOPROTEASE ENZYME INHIBITOR | PHARMACIA CORPORATION | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034071-A1 | Thioaryl sulfonamide hydroxamic acid compounds | MMP10, MMP1, MMP3 | BMP1 2589/4885MMP3 3/4885MEN1 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.